SVB Wealth LLC Decreases Position in Amgen Inc. $AMGN

SVB Wealth LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 26.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,655 shares of the medical research company’s stock after selling 1,304 shares during the quarter. SVB Wealth LLC’s holdings in Amgen were worth $1,324,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Pinnacle Wealth Management Advisory Group LLC raised its stake in shares of Amgen by 5.4% during the second quarter. Pinnacle Wealth Management Advisory Group LLC now owns 14,622 shares of the medical research company’s stock valued at $5,295,000 after purchasing an additional 746 shares during the period. Integrated Wealth Concepts LLC boosted its stake in shares of Amgen by 2.3% in the second quarter. Integrated Wealth Concepts LLC now owns 24,183 shares of the medical research company’s stock valued at $8,757,000 after purchasing an additional 541 shares during the period. Community Bank N.A. boosted its stake in shares of Amgen by 1.3% in the second quarter. Community Bank N.A. now owns 16,708 shares of the medical research company’s stock valued at $6,050,000 after purchasing an additional 216 shares during the period. RFG Advisory LLC grew its holdings in Amgen by 2.9% during the 2nd quarter. RFG Advisory LLC now owns 14,031 shares of the medical research company’s stock valued at $5,081,000 after purchasing an additional 399 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in Amgen by 8.5% during the 2nd quarter. IFP Advisors Inc now owns 8,216 shares of the medical research company’s stock valued at $2,975,000 after purchasing an additional 643 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 0.5%

AMGN opened at $391.27 on Thursday. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $447.03. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The stock has a market capitalization of $211.53 billion, a PE ratio of 24.32, a P/E/G ratio of 2.83 and a beta of 0.43. The firm’s fifty day moving average price is $400.14 and its 200 day moving average price is $367.79.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period last year, the business earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts expect that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on AMGN shares. Canaccord Genuity Group boosted their price objective on shares of Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Guggenheim raised their target price on Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. TD Cowen lifted their target price on Amgen from $420.00 to $452.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Mizuho boosted their price target on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. Finally, Argus increased their price target on Amgen from $375.00 to $460.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $381.68.

Insider Activity

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by corporate insiders.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported that the Phase 3 DeLLphi-305 trial met its primary endpoint. Imdelltra combined with Imfinzi significantly improved overall survival in first-line extensive-stage small-cell lung cancer and also met progression-free survival and response-rate endpoints, strengthening the commercial outlook for Imdelltra. Amgen Imdelltra Phase 3 results
• Positive Sentiment: William Blair maintained a Buy rating, citing the Imdelltra Phase 3 success as support for Amgen’s pipeline and investment case. Piper Sandler also reaffirmed its Buy rating. Imdelltra analyst rating
• Neutral Sentiment: Amgen is scheduled to present at the Morgan Stanley Global Healthcare Conference, potentially providing updates on olpasiran, Imdelltra and broader pipeline priorities. Amgen Morgan Stanley conference presentation
• Neutral Sentiment: Analyst views remain mixed: Wells Fargo reiterated Hold, while Cantor Fitzgerald maintained Neutral with a $400 price target, suggesting limited near-term upside from recent levels. Wells Fargo Amgen rating
• Negative Sentiment: Novartis’ Phase 3 pelacarsen trial failed to reduce cardiovascular events despite lowering Lp(a), raising doubts about whether the biomarker translates into clinical benefits. Investors consequently questioned the prospects for Amgen’s olpasiran, which remains in a large late-stage heart-outcomes study. Novartis cholesterol drug setback
• Negative Sentiment: BMO downgraded Amgen to Market Perform from Outperform, citing a less favorable risk-reward balance and limited near-term upside. Broader market pressure from higher oil prices, inflation concerns and interest-rate uncertainty has added to selling pressure. BMO Amgen downgrade

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.